罗欣药业：预计2025年前三季度净利润2270万元~2520万元

Group 1 - The core point of the article is that Luoxin Pharmaceutical (SZ 002793) expects to achieve a net profit of 22.7 million to 25.2 million yuan for the first three quarters of 2025, marking a turnaround from a loss in the previous year [1] - The basic earnings per share are projected to be between 0.0214 yuan and 0.0237 yuan, compared to a loss of 0.2486 yuan per share in the same period last year [1] - The main reason for the performance change is the deepening commercialization process of the core innovative drug, Tegoprazan tablets, which has seen significant sales growth due to market expansion efforts [1] - The company has improved its operating cash flow and reduced bad debt losses through effective management of accounts receivable [1] - For the first half of 2025, the revenue composition of Luoxin Pharmaceutical is expected to be 88.11% from pharmaceutical manufacturing, 10.1% from pharmaceutical commerce, and 1.79% from other businesses [1] Group 2 - As of the report date, Luoxin Pharmaceutical has a market capitalization of 5.3 billion yuan [2]